What is Wedbush’s Forecast for Rezolute Q3 Earnings?

Rezolute, Inc. (NASDAQ:RZLT) – Wedbush issued their Q3 2026 earnings estimates for shares of Rezolute in a research report issued on Thursday, September 18th. Wedbush analyst Y. Zhong expects that the company will earn ($0.27) per share for the quarter. Wedbush has a “Outperform” rating and a $12.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. Wedbush also issued estimates for Rezolute’s FY2030 earnings at $0.71 EPS.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03).

A number of other equities analysts have also recently issued reports on RZLT. BTIG Research reiterated a “buy” rating and set a $17.00 price objective on shares of Rezolute in a research report on Thursday. Maxim Group upped their price target on shares of Rezolute from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and an average price target of $14.40.

Rezolute Price Performance

RZLT stock opened at $7.70 on Monday. The company has a 50 day simple moving average of $6.62 and a 200 day simple moving average of $4.74. The stock has a market cap of $699.24 million, a price-to-earnings ratio of -7.94 and a beta of 0.02. Rezolute has a 1 year low of $2.21 and a 1 year high of $8.81.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RZLT. Federated Hermes Inc. boosted its stake in Rezolute by 24.4% during the second quarter. Federated Hermes Inc. now owns 14,034,712 shares of the company’s stock worth $62,595,000 after acquiring an additional 2,755,385 shares in the last quarter. Rosalind Advisors Inc. bought a new position in Rezolute during the second quarter worth $7,766,000. Geode Capital Management LLC boosted its stake in Rezolute by 201.7% during the second quarter. Geode Capital Management LLC now owns 1,711,043 shares of the company’s stock worth $7,633,000 after acquiring an additional 1,143,834 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Rezolute by 56.4% in the second quarter. Marshall Wace LLP now owns 2,886,481 shares of the company’s stock valued at $12,874,000 after buying an additional 1,041,234 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in shares of Rezolute by 77.4% in the second quarter. Nantahala Capital Management LLC now owns 2,291,395 shares of the company’s stock valued at $10,220,000 after buying an additional 1,000,000 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.